CME webinars help oncologists treat advanced prostate cancer and navigate those patients through the COVID-19 pandemic

Already challenged by rapid advances in the treatment of advanced prostate cancer, oncologists in the past year also have been forced to revamp their clinical practices during the COVID-19 pandemic. Patients with cancer are at greater risk for infection or complications from COVID-19, necessitating a switch from in-person care to the relatively new arena of telemedicine. To help oncologists navigate new treatment options for advanced prostate cancer while protecting their patients during the pandemic, Rockpointe and the Potomac Center for Medical Education will offer the latest guidance during three live CME/CPE/MOC-eligible webinars (March 16, March 24, and April 15).

From the introduction of chemotherapy and androgen inhibitors to the metastatic hormone-sensitive prostate cancer (HSPC) setting, to the recognition of non-metastatic castration-resistant prostate cancer (nmCRPC) as a disease state with multiple effective treatment options, the treatment of advanced prostate cancer has changed significantly in recent years. With the increased reliance on telemedicine, oncologists require guidance on how to ensure patient safety during the pandemic, how to incorporate telemedicine into their practices, and how to continue to provide excellent patient care in this new format. Managing Advanced Prostate Cancer in the COVID-19 Era: What Do Oncologists Need to Know? is an hour-long program geared toward oncologists and other clinicians involved in the management of patients with prostate cancer. Participants will receive the most up-to-date evidence-based information and expert guidance on selecting and sequencing therapies in advanced prostate cancer and managing patient care during the COVID-19 pandemic.

Dates and times

Tuesday, March 16, 2021
4:00 – 5:00 PM ET (3:00 – 4:00 PM CT / 1:00 – 2:00 PM PT)

Wednesday, March 24, 2021
7:00 – 8:00 PM ET (6:00 – 7:00 PM CT / 4:00 – 5:00 PM PT)

Thursday, April 15, 2021
12:00 – 1:00 PM ET (11:00 AM – 12:00 PM CT / 9:00 – 10:00 AM PT)

This free educational initiative is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine; and to address ACPE competencies, including foundational knowledge and essentials for practice and care. At the program’s conclusion, participants should be able to:

• Evaluate current and emerging treatments for patients with advanced prostate cancer based on clinical trial safety and efficacy data.
• Develop patient-personalized treatment plans for advanced prostate cancer across all stages of disease.
• Integrate consensus recommendations for the safe and effective management of prostate cancer during the COVID-19 pandemic.
• Adopt recommended practices for appropriate integration of telemedicine into prostate cancer care.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education (PCME) and Rockpointe. PCME, which is accredited by the ACCME to provide continuing medical education for physicians, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.

Successful completion of this CME activity, which includes participation in the evaluation component, enables participants to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

PCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE) and designates this application-based activity for a maximum of 1.0 contact hour (0.10 CEU) of continuing education credit.

There is no fee for this activity, which is supported by educational grants from Astellas/Pfizer and Exelixis. To receive credit, participants must register, view the live CME/CE activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

Through effective continuing medical education, Rockpointe strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, such as managing challenges posed by COVID-19, addressing racial disparities in care, and combating the nation’s opioid crisis. Additional available courses for COVID-19 include Dermatology, Diabetes, Obesity, Lung Cancer, Clinical Management, and Asthma and Telemedicine.

As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy and Medicine. In addition, its popular Medical Education Exchange (MEDX) CME regional meetings include sessions on the basics of quality improvement and alternative payment models, as well as relevant and scientifically accurate sessions on numerous disease states. All sessions include links back to associated National Quality Priorities to reinforce the bigger picture and the triple aim of: 1) improving health and 2) lowering cost to 3) better the patient experience. At Rockpointe, education equals quality.

For more details and to register for Managing Advanced Prostate Cancer in the COVID-19 Era, go to https://www.pathlms.com/rockpointe/courses/27637 or click here.